xtag
tm
rvp
assay
rvp
multiplex
nucleicacid
base
molecular
test
capabl
detect
virus
subtyp
simultan
singl
patient
sampl
assay
protocol
discuss
elsewher
supplement
present
articl
describ
analyt
perform
select
clinic
result
assay
design
requir
xtag
rvp
assay
establish
consult
lead
clinic
laboratori
expert
field
part
design
valid
process
preclin
test
xtag
tm
rvp
assay
carri
intern
research
product
develop
depart
luminex
molecular
diagnost
follow
extern
set
preclin
studi
lead
multicentr
clinic
trial
achiev
fda
clearanc
taken
togeth
preclin
clinic
result
valid
perform
assay
state
design
requir
clinic
multisit
trial
still
ongo
close
complet
therefor
final
data
summari
clinic
trial
includ
articl
except
ce
mark
fda
submit
analyt
data
howev
earlier
extern
evalu
xtag
tm
rvp
assay
use
clinic
sampl
publish
mahoni
et
al
note
fact
data
deriv
assay
evalu
fda
clinic
trial
design
studi
similar
perform
data
assay
avail
time
public
supplement
pleas
contact
luminex
molecular
diagnost
last
author
articl
inform
ongo
clinic
multicentr
studi
rvp
assay
evalu
direct
immunofluor
assay
dfa
cultur
test
method
prospect
use
nasopharyng
np
swab
sampl
collect
clinic
site
specimen
collect
individu
undergo
routin
respiratori
viru
test
flu
season
preclin
studi
report
mahoni
et
al
np
specimen
prospect
collect
univers
transport
medium
divid
aliquot
one
aliquot
process
virolog
laboratori
dfa
shell
vial
cultur
wherea
anoth
aliquot
test
rvp
assay
initi
data
indic
dfacultur
detect
posit
rvp
detect
specimen
howev
rvp
also
detect
addit
posit
specimen
detect
dfacultur
next
step
discord
sampl
test
specif
revers
transcriptas
rt
pcr
assay
use
uniqu
primer
pair
viral
target
differ
primer
employ
rvp
assay
sampl
confirm
true
posit
rtpcr
method
analysi
data
follow
confirmatori
test
suggest
rvp
greater
clinic
sensit
dfacultur
rvp
detect
true
posit
oppos
dfacultur
detect
posit
sampl
appar
clinic
sensit
includ
confirm
posit
rvp
assay
detect
posit
dfacultur
clinic
specif
high
methodolog
rvp
dfacultur
rvp
detect
specimen
dfacultur
capabl
detect
specimen
dfacultur
test
rvp
assay
detect
dual
infect
specimen
trend
case
number
may
small
draw
conclus
larger
popul
dual
infectionposit
patient
collect
import
dual
infect
complet
clear
possibl
treatment
strategi
infect
control
decis
may
influenc
occurr
clinic
multicentr
trial
final
data
complet
avail
shortli
studi
multicentr
evalu
involv
site
north
america
europ
respiratori
tract
specimen
clinic
inform
collect
manner
studi
mahoni
et
al
sampl
aliquot
test
dfacultur
rvp
specimen
discord
result
test
either
rtpcr
method
agaros
gel
analysi
dideoxysequenc
pcr
product
establish
final
perform
data
studi
specimen
divid
gender
age
infant
adult
symptom
base
upon
medic
chart
review
hospit
statu
outpati
hospit
emerg
depart
extend
care
facil
site
use
extract
method
easymag
tm
minimag
tm
qiagen
qiaamp
minelut
specimen
collect
date
analyz
use
common
set
reagent
lot
accessori
part
valid
process
rvp
assay
set
analyt
studi
carri
establish
robust
assay
studi
includ
precis
reproduc
limit
detect
accuraci
detect
interf
substanc
analyt
reactiv
stabil
data
part
fda
submiss
except
precisionreproduc
studi
deriv
ce
mark
assay
singlesit
evalu
precis
carri
plasmid
control
establish
baselin
variabl
xtag
tm
rvp
assay
rtpcr
tspe
data
acquisit
data
analysi
studi
involv
total
run
carri
span
day
test
variabl
across
ancillari
reagent
lot
qiagen
enzym
mix
qiagen
onestep
rtpcr
kit
lot
takara
dna
polymeras
lot
roch
shrimp
alkalin
phosphatas
instrument
thermocycl
luminex
instrument
lot
xtag
tm
rvp
kit
overal
percentag
expect
call
observ
across
sampl
repres
viral
type
subtyp
probe
assay
arm
multisit
evalu
reproduc
carri
viral
isolatesin
vitro
transcrib
rna
establish
reproduc
entir
system
sampl
extract
plu
xtag
tm
rvp
test
across
site
run
carri
across
day
site
also
establish
reproduc
within
across
extract
method
extract
day
extract
method
across
lot
xtag
tm
rvp
kit
lot
reproduc
studi
arm
sitetosit
reproduc
three
site
test
replic
singleposit
specimen
prepar
dilut
one
limit
detect
lod
one
one
either
replic
per
dilut
dualposit
specimen
sampl
one
viru
present
low
titer
high
titer
replic
one
neg
specimen
replic
sampl
test
run
carri
across
day
site
sampl
test
list
tabl
togeth
expect
call
made
xtag
tm
rvp
replic
simul
singleposit
sampl
target
probe
xtag
tm
rvp
see
tabl
test
across
extract
method
qiagen
qiaamp
minelut
easymag
tm
minimag
tm
extract
day
lot
xtag
tm
rvp
determin
interintra
extract
variabl
interlot
variabl
extract
methodtomethod
reproduc
assess
determin
combin
extract
day
rvp
lot
day
lot
day
lot
day
lot
combin
total
overal
percentag
expect
call
across
sampl
extract
separ
method
easymag
tm
minimag
tm
qiaamp
minelut
see
tabl
extract
daytoday
reproduc
combin
extract
method
rvp
lot
method
lot
method
lot
method
lot
combin
total
overal
percentag
expect
call
across
sampl
extract
separ
day
see
tabl
rvp
lottolot
reproduc
assess
determin
combin
extract
method
extract
day
method
day
method
day
method
day
combin
total
overal
percentag
expect
call
across
sampl
assay
separ
lot
see
tabl
overal
reproduc
within
extract
method
assess
determin
extract
method
evalu
overal
percentag
expect
call
across
sampl
extract
separ
day
assay
differ
rvp
lot
tabl
overal
reproduc
across
extract
method
day
rvp
lot
assess
determin
overal
reproduc
result
combin
extract
day
rvp
lot
extract
method
consid
togeth
sampl
test
tabl
limit
detect
lod
xtag
tm
rvp
evalu
use
sampl
list
tabl
sampl
test
tabl
indic
lowest
analyt
level
test
replic
gener
posit
call
ie
lowest
test
analyt
level
beta
risk
risk
type
ii
error
relat
evalu
limit
blank
lob
probabl
targetneg
specimen
gener
mfi
read
target
ie
lob
set
ensur
alpha
risk
risk
type
error
character
isol
cell
cultur
flu
posit
human
specimen
use
establish
analyt
accuraci
flu
detect
accuraci
assess
term
abil
rvp
specif
detect
matrix
gene
variant
hemagglutinin
gene
result
summar
tabl
worth
note
target
probe
specimen
gener
neg
result
ie
mfi
juli
th
confirm
case
highli
pathogen
avian
flu
report
world
health
organ
http
wwwwhointcrsdiseaseavian
influenzaen
luminex
molecular
diagnost
conduct
sequenc
align
analys
primer
vs
recent
data
avail
ncbi
genbank
http
wwwncbinlmnihgovgenbank
data
reveal
signific
primer
mismatch
would
predict
neg
affect
abil
rvp
detect
hemagglutinin
target
specimen
nasopharyng
swab
collect
two
north
american
site
analyz
term
clinic
specif
subtyp
influenza
total
clinic
specimen
analyz
term
fals
posit
true
neg
result
target
rvp
identifi
specimen
neg
clinic
specif
ci
matrix
effect
evalu
assay
artifici
construct
eg
purifi
plasmid
phage
lambda
dna
rna
simul
clinic
sampl
eg
cell
cultur
lysat
contain
rsva
flua
also
contain
spikedin
phage
presenc
potenti
interfer
viral
transport
medium
vtm
nasopharyng
swab
np
nasal
aspir
na
potenti
interfer
vv
exert
inhibitori
effect
xtag
tm
rvp
run
purifi
plasmid
assay
purifi
rna
unaffect
vv
vtm
np
inhibit
na
shown
titrat
detect
rsva
flua
intern
control
extract
simul
sampl
sever
inhibit
presenc
vtm
np
na
presenc
potenti
interfer
note
inhibit
xtag
tm
rvp
matrix
effect
detect
decreas
mfi
intern
control
thu
essenti
spike
intern
control
sampl
extract
activeinact
ingredi
medic
typic
prescrib
treat
respiratori
tract
infect
taken
oral
would
present
anatom
collect
site
nasopharynx
andor
bronchiol
neglig
quantiti
affect
xtag
tm
rvp
assay
human
cellular
materi
might
present
clinic
specimen
consequ
human
genom
dna
might
carri
extract
procedur
extract
sampl
test
interfer
effect
purifi
human
genom
dna
ng
per
reaction
spike
posit
control
mixtur
recombin
plasmid
contain
viral
target
sequenc
compar
unspik
control
sampl
human
genom
dna
ngreaction
interfer
identif
viral
nucleic
acid
experi
sixteen
combin
rvp
analyt
target
potenti
bacteri
viral
interfer
extract
live
cultur
assess
potenti
interfer
chosen
basi
caus
agent
respiratori
infect
target
xtag
tm
rvp
report
scientif
literatur
coinfect
pathogen
viral
agent
target
xtag
tm
rvp
result
summar
tabl
tabl
shelflif
xtag
tm
rvp
kit
year
kit
reagent
store
typic
transport
condit
xtag
tm
rvp
kit
ship
custom
use
overnight
deliveri
servic
xtag
tm
rvp
assay
detect
respiratori
virus
subtyp
offer
signific
advantag
routinelyus
dfa
cultur
method
sinc
identifi
addit
virus
analyt
studi
support
versatil
robust
rvp
assay
well
abil
meet
design
requir
reproduc
studi
multipl
site
differ
extract
method
day
test
rvp
lot
target
gave
expect
call
percentag
lod
studi
support
superior
analyt
sensit
assay
compar
dfa
cultur
also
note
assay
high
degre
clinic
specif
sinc
background
gener
low
mfi
unit
compar
typic
posit
signal
mfi
unit
give
sn
ratio
posit
viral
target
cutoff
greater
mfi
unit
use
differenti
posit
result
call
neg
call
less
mfi
unit
thu
even
weak
posit
usual
distinct
sn
greater
interf
substanc
associ
matrix
effect
medic
purifi
human
genom
dna
virus
bacteria
affect
rvp
assay
perform
analyt
crossreact
data
varieti
common
bacteria
virus
indic
crossreact
sever
call
note
attribut
organ
rvp
assay
oneyear
shelf
life
proper
storag
condit
ampl
applic
summari
valu
xtag
rvp
becom
appar
given
larg
number
respiratori
virus
affect
human
assay
detect
virus
subtyp
wherea
dfa
cultur
typic
detect
virus
subtyp
xtag
rvp
also
gener
result
hour
compar
two
day
cultur
current
gold
standard
studi
reveal
rvp
like
detect
respiratori
virus
dfa
cultur
due
broader
rang
target
superior
analyt
sensit
respect
rtpcr
method
rvp
like
compar
analyt
sensit
howev
multiplex
capabl
assay
make
test
power
tool
clinic
public
health
set
sinc
import
abl
detect
broad
rang
viral
target
simultan
determin
respiratori
virus
present
treatment
purpos
infect
control
cohort
report
public
health
flu
sarscov
